Truong Dongngan T, Trachtenberg Felicia L, Hu Chenwei, Pearson Gail D, Friedman Kevin, Sabati Arash A, Dionne Audrey, Oster Matthew E, Anderson Brett R, Block Joseph, Bradford Tamara T, Campbell M Jay, D'Addese Laura, Dummer Kirsten B, Elias Matthew D, Forsha Daniel, Garuba Olukayode D, Hasbani Keren, Hayes Kerri, Hebson Camden, Jone Pei-Ni, Krishnan Anita, Lang Sean, McCrindle Brian W, McHugh Kimberly E, Mitchell Elizabeth C, Morrison Tonia, Muniz Juan Carlos, Payne R Mark, Portman Michael A, Russell Mark W, Sanil Yamuna, Shakti Divya, Sharma Kavita, Shea J Ryan, Sykes Michelle, Shekerdemian Lara S, Szmuszkovicz Jacqueline, Thacker Deepika, Newburger Jane W
Division of Cardiology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City.
Now with Children's Healthcare of Atlanta Cardiology, Emory University School of Medicine, Atlanta, Georgia.
JAMA Pediatr. 2025 Mar 1;179(3):293-301. doi: 10.1001/jamapediatrics.2024.5466.
Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening complication of COVID-19 infection. Data on midterm outcomes are limited.
To characterize the frequency and time course of cardiac dysfunction (left ventricular ejection fraction [LVEF] <55%), coronary artery aneurysms (z score ≥2.5), and noncardiac involvement through 6 months after MIS-C.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study enrolled participants between March 2020 and January 2022 with a follow-up period of 2 years. Participants were recruited from 32 North American pediatric hospitals, and all participants met the 2020 Centers for Disease Control and Prevention case definition of MIS-C.
MIS-C after COVID-19 infection.
Outcomes included echocardiography core laboratory (ECL) assessments of LVEF and maximum coronary artery z scores (zMax); data collection on cardiac and noncardiac sequelae during hospitalization and at 2 weeks, 6 weeks, and 6 months after discharge; and age-appropriate Patient-Reported Outcomes Measurement Information Systems (PROMIS) Global Health Instruments at follow-up. Descriptive statistics, linear regression models, and Kaplan-Meier analysis were used.
Of 1204 participants (median [IQR] age, 9.1 [5.6-12.7] years; 724 male [60.1%]), 325 self-identified with non-Hispanic Black race (27.0%) and 324 with Hispanic ethnicity (26.9%). A total of 548 of 1195 participants (45.9%) required vasoactive support, 17 of 1195 (1.4%) required extracorporeal membrane oxygenation, and 3 (0.3%) died during hospitalization. Of participants with echocardiograms reviewed by the ECL (n = 349 due to budget constraints), 131 of 322 (42.3%) had LVEF less than 55% during hospitalization; of those with follow-up, all but 1 normalized by 6 months. Black race (vs other/unknown race), higher C-reactive protein level, and abnormal troponin level were associated with lowest LVEF (estimate [SE], -3.09 [0.98]; R2 = 0.14; P =.002). Fifteen participants had coronary artery z scores of 2.5 or greater at any time point; 1 participant had a large/giant aneurysm. Of the 13 participants with z scores of 2.5 or greater during hospitalization, 12 (92.3%) had normalized by 6 months. Return to greater than 90% of pre-MIS-C health status (energy, sleep, appetite, cognition, and mood) was reported by 711 of 824 participants (86.3%) at 2 weeks, increasing to 548 of 576 (95.1%) at 6 months. Fatigue was the most common symptom reported at 2 weeks (141 of 889 [15.9%]), falling to 3.4% (22 of 638) by 6 months. PROMIS Global Health parent/guardian proxy median T scores for fatigue, global health, and pain interference improved significantly from 2 weeks to 6 months (fatigue, 56.1 vs 48.9; global health, 48.8 vs 51.3; pain interference, 53.0 vs 43.3; P < .001) and by the 6-week visit were at least equivalent to prepandemic population norms.
Results of this cohort study suggest that although children and young adults with MIS-C can have severe disease during the acute phase, most recovered quickly and had a reassuring midterm prognosis.
儿童多系统炎症综合征(MIS-C)是新冠病毒感染的一种危及生命的并发症。关于中期结果的数据有限。
描述MIS-C后6个月内心脏功能障碍(左心室射血分数[LVEF]<55%)、冠状动脉瘤(z评分≥2.5)和非心脏受累的发生频率及时间进程。
设计、背景和参与者:这项队列研究纳入了2020年3月至2022年1月期间的参与者,随访期为2年。参与者从32家北美儿科医院招募,所有参与者均符合2020年美国疾病控制与预防中心MIS-C的病例定义。
新冠病毒感染后的MIS-C。
结局包括超声心动图核心实验室(ECL)对LVEF和最大冠状动脉z评分(zMax)的评估;住院期间以及出院后2周、6周和6个月时心脏和非心脏后遗症的数据收集;随访时使用适合年龄的患者报告结局测量信息系统(PROMIS)全球健康工具。采用描述性统计、线性回归模型和Kaplan-Meier分析。
1204名参与者(年龄中位数[四分位间距]为9.1[5.6 - 12.7]岁;724名男性[60.1%])中,325人自我认定为非西班牙裔黑人(27.0%),324人是西班牙裔(26.9%)。1195名参与者中共有548人(45.9%)需要血管活性支持,1195人中有17人(1.4%)需要体外膜肺氧合,3人(共0.3%)在住院期间死亡。经ECL审查超声心动图的参与者(由于预算限制,n = 349)中,322人中有131人(42.3%)在住院期间LVEF低于55%;在有随访的参与者中,除1人外,其余在6个月时均恢复正常。黑人种族(与其他/未知种族相比)、较高的C反应蛋白水平和肌钙蛋白水平异常与最低的LVEF相关(估计值[标准误],-3.09[0.98];R2 = 0.14;P = 0.002)。15名参与者在任何时间点的冠状动脉z评分为2.5或更高;1名参与者有一个大的/巨大的动脉瘤。在住院期间z评分为2.5或更高的13名参与者中,12人(92.3%)在6个月时恢复正常。824名参与者中有711人(86.3%)在2周时报告恢复到MIS-C前健康状态的90%以上(精力、睡眠、食欲、认知和情绪),到6个月时增至576人中有548人(95.1%)。疲劳是2周时报告的最常见症状(889人中有141人[15.9%]),到6个月时降至3.4%(638人中有22人)。从2周到6个月,PROMIS全球健康家长/监护人代理疲劳、总体健康和疼痛干扰的中位数T评分显著改善(疲劳,56.1对48.9;总体健康,48.8对51.3;疼痛干扰,53.0对43.3;P < 0.001),到6周就诊时至少相当于疫情前人群的标准。
这项队列研究的结果表明,尽管患有MIS-C的儿童和年轻人在急性期可能患有严重疾病,但大多数人恢复迅速,中期预后令人放心。